OR WAIT null SECS
November 03, 2020
The agreement will provide capacity for the manufacturing of AZD7442, currently being developed for the potential prevention and treatment of COVID-19, at Lonza's Portsmouth, NH site.
October 16, 2020
The new VirusExpress lentiviral production platform increases dose yields and reduces process development time for cell and gene therapies.
The new facility at the company’s San Diego, CA, site will be for late phase and commercial CGMP manufacturing.
October 01, 2020
The technology is a novel, plasmid-free manufacturing system for robust and reproducible manufacture of AAV at scale.
September 18, 2020
The collaboration will expand the manufacturing capacity for lenzilumab, a COVID-19 therapeutic candidate, in advance of a potential Emergency Use Authorization in 2020.
The agreement will Increase global manufacturing capacity for Novavax’s vaccine candidate, NVX-CoV2373, to more than two-billion annualized doses when at full capacity in 2021.
The agreement between the two companies will significantly increase global supply capacity for Lilly's potential COVID-19 treatments.
September 14, 2020
The investment will include new manufacturing lines and increased automation to deliver additional manufacturing capacity.
September 09, 2020
The investment at its Madison, WI, facility will expand MilliporeSigma’s capacity for high-potent active pharmaceutical ingredient production and allow for continuous flow manufacturing of ADCs.
The company is investing $130 million to add Phase III through commercial-scale manufacturing suites to its gene therapy campus in Harmans, MD.